Andrew P Byrnes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7724422/publications.pdf

Version: 2024-02-01

236612 377514 2,407 39 25 34 citations h-index g-index papers 39 39 39 1780 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Interaction of adenovirus with antibodies, complement, and coagulation factors. FEBS Letters, 2019, 593, 3449-3460.	1.3	32
2	Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum. PLoS ONE, 2018, 13, e0192353.	1.1	8
3	Evaluating the Impact of Natural IgM on Adenovirus Type 5 Gene Therapy Vectors. Methods in Molecular Biology, 2017, 1643, 187-196.	0.4	3
4	Adenovirus Vector Toxicity., 2017,, 37-60.		5
5	Antibodies against Adenoviruses. , 2016, , 367-390.		3
6	46. Shielding of Ad5 by Minimal Geneti-Chemical Modification: Preventing Clearance While Preserving Infectivity. Molecular Therapy, 2015, 23, S20.	3.7	0
7	Impact of Natural IgM Concentration on Gene Therapy with Adenovirus Type 5 Vectors. Journal of Virology, 2015, 89, 3412-3416.	1.5	29
8	Circulating Antibodies and Macrophages as Modulators of Adenovirus Pharmacology. Journal of Virology, 2013, 87, 3678-3686.	1.5	49
9	Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nature Medicine, 2013, 19, 452-457.	15.2	139
10	Breakout Session C Summary: Current Virus Detection Methods. PDA Journal of Pharmaceutical Science and Technology, 2011, 65, 660-662.	0.3	0
11	The Role of Endosomal Escape and Mitogen-Activated Protein Kinases in Adenoviral Activation of the Innate Immune Response. PLoS ONE, 2011, 6, e26755.	1.1	16
12	Induction of Shock After Intravenous Injection of Adenovirus Vectors: A Critical Role for Platelet-activating Factor. Molecular Therapy, 2010, 18, 609-616.	3.7	26
13	Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo. Journal of Virology, 2009, 83, 5648-5658.	1.5	72
14	A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells. Journal of Virological Methods, 2008, 147, 54-60.	1.0	38
15	Interaction of Systemically Delivered Adenovirus Vectors with Kupffer Cells in Mouse Liver. Human Gene Therapy, 2008, 19, 547-554.	1.4	55
16	Clearance of Adenovirus by Kupffer Cells Is Mediated by Scavenger Receptors, Natural Antibodies, and Complement. Journal of Virology, 2008, 82, 11705-11713.	1.5	170
17	Th1 cytokines are upregulated by adenoviral vectors in the brains of primed mice. NeuroReport, 2008, 19, 1187-1192.	0.6	4
18	Quality prediction of cell substrate using gene expression profiling. Genomics, 2006, 87, 552-559.	1.3	17

#	Article	IF	Citations
19	Heparin-binding and patterns of virulence for two recombinant strains of Sindbis virus. Virology, 2006, 347, 183-190.	1.1	27
20	Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Molecular Therapy, 2006, 13, 108-117.	3.7	117
21	Challenges and future prospects in gene therapy. IDrugs: the Investigational Drugs Journal, 2005, 8, 993-6.	0.7	0
22	Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Molecular Therapy, 2004, 9, 932-941.	3.7	52
23	Unexpected pulmonary uptake of adenovirus vectors in animals with chronic liver disease. Gene Therapy, 2004, 11, 431-438.	2.3	46
24	Humoral immune responses to adenovirus vectors in the brain. Journal of Neuroimmunology, 2000, 103, 8-15.	1.1	41
25	Control of Sindbis Virus Infection by Antibody in Interferon-Deficient Mice. Journal of Virology, 2000, 74, 3905-3908.	1.5	59
26	Large-Plaque Mutants of Sindbis Virus Show Reduced Binding to Heparan Sulfate, Heightened Viremia, and Slower Clearance from the Circulation. Journal of Virology, 2000, 74, 644-651.	1.5	118
27	Characterization of a Chinese Hamster Ovary Cell Line Developed by Retroviral Insertional Mutagenesis That Is Resistant to Sindbis Virus Infection. Journal of Virology, 1999, 73, 4919-4924.	1.5	18
28	Potential and limitations of a $\hat{1}^3$ 34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS. Gene Therapy, 1998, 5, 594-604.	2.3	24
29	Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina. Gene Therapy, 1998, 5, 1561-1565.	2.3	25
30	Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. European Journal of Immunology, 1998, 28, 3904-3916.	1.6	48
31	A $\hat{1}^3$ 34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience, 1998, 83, 1225-1237.	1.1	59
32	Binding of Sindbis Virus to Cell Surface Heparan Sulfate. Journal of Virology, 1998, 72, 7349-7356.	1.5	257
33	Immune Responses to Adenoviral Vectors During Gene Transfer in the Brain. Human Gene Therapy, 1997, 8, 253-265.	1.4	97
34	Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. Gene Therapy, 1997, 4, 639-647.	2.3	89
35	Immune responses to adenovirus vectors in the nervous system. Trends in Neurosciences, 1996 , 19 , $497-501$.	4.2	162
36	Immunological Instability of Persistent Adenovirus Vectors in the Brain: Peripheral Exposure to Vector Leads to Renewed Inflammation, Reduced Gene Expression, and Demyelination. Journal of Neuroscience, 1996, 16, 3045-3055.	1.7	153

Andrew P Byrnes

#	Article	IF	CITATIONS
37	Adenovirus gene transfer causes inflammation in the brain. Neuroscience, 1995, 66, 1015-1024.	1.1	289
38	Specific Patterns of Defective HSV-1 Gene Transfer in the Adult Central Nervous System: Implications for Gene Targeting. Experimental Neurology, 1994, 130, 127-140.	2.0	42
39	Molecular cloning of a G-protein ai subunit from the lobster olfactory organ. Molecular Brain Research, 1992, 14, 273-276.	2.5	18